Cantor Fitzgerald maintains an 'Buy' on ImmunoGen, Inc. (Nasdaq: IMGN), lowers PT from $13 to $7.

Cantor analyst says, "We ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE